Citigroup’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17M Buy
421,067
+386,938
+1,134% +$14.5M 0.01% 1163
2025
Q4
$1.19M Sell
34,129
-41,383
-55% -$3.25M ﹤0.01% 3023
2025
Q3
$6.28M Sell
75,512
-21,739
-22% -$1.57M ﹤0.01% 1818
2025
Q2
$7.14M Sell
97,251
-62,909
-39% -$4.56M ﹤0.01% 1618
2025
Q1
$18.3M Buy
160,160
+15,915
+11% +$969K 0.01% 1023
2024
Q4
$7.27M Sell
144,245
-461
-0.3% -$24.2K ﹤0.01% 1625
2024
Q3
$6.7M Buy
144,706
+48,270
+50% +$1.72M ﹤0.01% 1609
2024
Q2
$3.13M Sell
96,436
-10,515
-10% -$288K ﹤0.01% 1987
2024
Q1
$2.69M Buy
106,951
+28,079
+36% +$663K ﹤0.01% 2189
2023
Q4
$2.56M Buy
78,872
+27,054
+52% +$743K ﹤0.01% 2038
2023
Q3
$1.41M Sell
51,818
-35,116
-40% -$1.02M ﹤0.01% 2250
2023
Q2
$1.93M Buy
86,934
+14,248
+20% +$328K ﹤0.01% 2248
2023
Q1
$1.57M Sell
72,686
-2,072
-3% -$45.4K ﹤0.01% 2188
2022
Q4
$1.52M Buy
74,758
+3,823
+5% +$95.8K ﹤0.01% 2259
2022
Q3
$1.82M Buy
70,935
+2,168
+3% +$58K ﹤0.01% 2215
2022
Q2
$1.64M Sell
68,767
-34,474
-33% -$751K ﹤0.01% 2258
2022
Q1
$2.33M Buy
103,241
+13,488
+15% +$287K ﹤0.01% 2246
2021
Q4
$1.78M Buy
89,753
+2,396
+3% +$48.6K ﹤0.01% 2726
2021
Q3
$1.72M Sell
87,357
-964
-1% -$20.2K ﹤0.01% 2661
2021
Q2
$1.94M Buy
88,321
+48,373
+121% +$1.08M ﹤0.01% 2689
2021
Q1
$950K Sell
39,948
-15,978
-29% -$427K ﹤0.01% 3023
2020
Q4
$1.46M Sell
55,926
-30,200
-35% -$636K ﹤0.01% 3158
2020
Q3
$1.5M Sell
86,126
-36,624
-30% -$584K ﹤0.01% 2923
2020
Q2
$2.06M Buy
122,750
+29,642
+32% +$416K ﹤0.01% 2776
2020
Q1
$1.11M Sell
93,108
-14,582
-14% -$180K ﹤0.01% 3064
2019
Q4
$1.3M Sell
107,690
-32,144
-23% -$447K ﹤0.01% 3478
2019
Q3
$1.98M Buy
139,834
+49,335
+55% +$606K ﹤0.01% 2881
2019
Q2
$1.01M Sell
90,499
-39,596
-30% -$441K ﹤0.01% 3620
2019
Q1
$1.53M Sell
130,095
-80,198
-38% -$997K ﹤0.01% 2956
2018
Q4
$2.81M Buy
210,293
+104,784
+99% +$1.38M ﹤0.01% 2348
2018
Q3
$1.48M Sell
105,509
-100,526
-49% -$1.4M ﹤0.01% 3059
2018
Q2
$3.24M Buy
206,035
+159,380
+342% +$2.77M ﹤0.01% 2235
2018
Q1
$767K Sell
46,655
-202,837
-81% -$3.76M ﹤0.01% 3520
2017
Q4
$4.51M Buy
249,492
+4,674
+2% +$84.7K ﹤0.01% 1929
2017
Q3
$4.72M Buy
244,818
+69,604
+40% +$1.04M ﹤0.01% 1825
2017
Q2
$2.07M Buy
175,214
+148,918
+566% +$1.62M ﹤0.01% 2559
2017
Q1
$288K Sell
26,296
-49,367
-65% -$434K ﹤0.01% 4340
2016
Q4
$549K Buy
75,663
+49,690
+191% +$389K ﹤0.01% 4276
2016
Q3
$169K Buy
25,973
+9,990
+63% +$58.1K ﹤0.01% 4791
2016
Q2
$88K Sell
15,983
-38,756
-71% -$202K ﹤0.01% 5179
2016
Q1
$256K Buy
54,739
+25,467
+87% +$99.2K ﹤0.01% 4848
2015
Q4
$146K Buy
29,272
+29,262
+292,620% +$132K ﹤0.01% 5032
2015
Q3
$0 Sell
10
-794
-99% -$4.03K ﹤0.01% 7415
2015
Q2
$5K Sell
804
-4,374
-84% -$26.8K ﹤0.01% 6733
2015
Q1
$29K Sell
5,178
-3,978
-43% -$14.4K ﹤0.01% 5854
2014
Q4
$27K Buy
9,156
+7,301
+394% +$22.3K ﹤0.01% 6066
2014
Q3
$5K Buy
1,855
+904
+95% +$2.39K ﹤0.01% 6549
2014
Q2
$3K Sell
951
-7,805
-89% -$23K ﹤0.01% 6612
2014
Q1
$38K Sell
8,756
-7,919
-47% -$27.7K ﹤0.01% 5661
2013
Q4
$54K Buy
16,675
+16,604
+23,386% +$33.6K ﹤0.01% 5673
2013
Q3
$0 Buy
71
+1
+1% +$2 ﹤0.01% 6811
2013
Q2
$0 Buy
+70
New +$126 ﹤0.01% 6744

Other funds holding CORT

Citigroup's CORT Position: Q1 2026 in Review

Citigroup increased its Corcept Therapeutics (CORT) stake by 1,134% in Q1 2026, buying an estimated $14.5M and bringing the position to 421,067 shares worth $17M. The position accounts for 0.01% of the portfolio, ranked #1163.

Citigroup first reported a position in CORT in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.3M in Q1 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Citigroup held 421,067 shares of Corcept Therapeutics worth $17M as of Q1 2026.
  • Citigroup bought 386,938 Corcept Therapeutics shares in Q1 2026, an estimated $14.5M.
  • Corcept Therapeutics made up 0.01% of Citigroup's portfolio in Q1 2026, its #1163 holding.
  • Citigroup first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Corcept Therapeutics position peaked at $18.3M in Q1 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.